Iterum Therapeutics to Report Second Quarter 2025 Financial Results on August 5, 2025
Iterum Therapeutics (Nasdaq: ITRM), a developer of next-generation oral and IV antibiotics, has scheduled its second quarter 2025 financial results announcement for August 5, 2025, before U.S. markets open.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Iterum Therapeutics (Nasdaq: ITRM), a developer of next-generation oral and IV antibiotics, has scheduled its second quarter 2025 financial results announcement for August 5, 2025, before U.S. markets open.
The company will host a conference call at 8:30 a.m. ET on the same day, where management will discuss financial results and provide a business update. Investors can access the call via phone using the numbers 833-470-1428 (domestic) or 404-975-4839 (international) with Access Code 740801. A webcast will be available on the company's investor relations website.
Details
News Market Reaction – ITRM
The recorded move for ITRM in the trading session of this news was -3.85%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DUBLIN, Ireland and CHICAGO, July 29, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its second quarter 2025 financial results before the open of the U.S. financial markets on Tuesday, August 5, 2025. Management will host a conference call at 8:30 a.m. ET that day to discuss the Company’s financial results and provide an update on its business.
To access the call please dial 833-470-1428 (domestic) or 404-975-4839 (international) and refer to Access Code 740801. To pre-register for this call, please go to the following link: https://events.q4inc.com/attendee/143945533. The audio webcast can be accessed under “Financials & Filings” in the Investors section of the Company’s website at www.iterumtx.com following the call.
About Iterum Therapeutics plc
Iterum Therapeutics plc is focused on delivering differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum is advancing the development of its first compound, sulopenem, a novel penem anti-infective compound, with an oral formulation and IV formulation. Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum has received approval of its NDA for ORLYNVAH™ (oral sulopenem) for the treatment of uncomplicated urinary tract infections caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women with limited or no alternative oral antibacterial treatment options by the U.S. Food and Drug Administration and has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications. For more information, please visit www.iterumtx.com.
Investor Contact:
Judy Matthews
Chief Financial Officer
312-778-6073
IR@iterumtx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.